Rhumbline Advisers Acumen Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
A detailed history of Rhumbline Advisers transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 45,516 shares of ABOS stock, worth $50,067. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,516
Previous 53,076
14.24%
Holding current value
$50,067
Previous $91,000
40.66%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ABOS
# of Institutions
81Shares Held
40.6MCall Options Held
28.6KPut Options Held
76.4K-
Ra Capital Management, L.P. Boston, MA14.9MShares$16.4 Million0.42% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$3.76 Million2.23% of portfolio
-
Franklin Resources Inc San Mateo, CA3.27MShares$3.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$2.37 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.94MShares$2.13 Million0.0% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $44.6M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...